Theralase targets completion of Study II enrollment this year for bladder cancer treatment Rudivar

Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) is eyeing regulatory approval for its lead asset, the bladder cancer treatment Rudivar, by 2026,...

Related Keywords

United States ,San Antonio ,Texas ,Canada ,American ,Canadian ,Kristina Hachey ,Health Canada ,Canadian Urologic Association Bladder Cancer Forum ,Theralase Technologies Inc ,Drug Division ,American Urology Association ,Urology Association ,